Test Directory

ROS1 gene rearrangement

Containers - Adult

FFPE block / H&E slide / Pathology report

Laboratory Site

RIE

51 Little France Crescent
Old Dalkeith Road
Edinburgh
EH16 4SA

Telephone: 0131 536 1000

Transport arrangements

Referral specimens should be sent directly to Molecular Pathology at the above address (see transport recommendations). For patients with pathology specimens held within NHS Lothian there is no need to arrange transport of specimens.

How to request

ROS1 gene rearrangement analysis can be requested individually or as part of the lung cancer panel.

Testing for NHS Lothian patients can be requested by email to molecular.pathology@nhslothian.scot.nhs.uk. Referral requests must be accompanied by a completed request form.

Molecular Pathology Request form v11_PDF.pdf

Please also refer to our detailed requesting instructions.

Availability

Monday - Friday. 09:00 – 17:00

Anticipated turnaround

An integrated Molecular Pathology report should be available within 10 working days. See results.

Static information/disclaimer

ROS1 FISH is accredited to ISO15189.

ROS1 Immunohistochemistry is not currently accredited to ISO15189.

Please note: alternative methodologies may be used. Full details will be included in all reports.

General additional information

The ROS proto-oncogene 1, receptor tyrosine kinase, encoded by the ROS1 gene, is structurally similar to the anaplastic lymphoma kinase (ALK) protein. ROS1 gene rearrangements involving a range of fusion partners have been described in 1-2% of non-small cell lung cancers, resulting in abnormal expression of the ROS1 protein. The presence of ROS1 gene rearrangement predicts response to the same classes of tyrosine kinase inhibitors used to treat ALK-positive lung cancers.

Immunohistochemistry is carried out to detect aberrant ROS1 protein expression using the D4D6 clone (Cell Signaling). ROS1 gene rearrangement analysis is carried out by fluorescence in-situ hybridization (FISH).

Analysis of the ROS1 gene is carried out as part of the lung cancer testing panel, which also includes EGFR and KRAS mutation analysis, PD-L1 expression and detection of ALK gene rearrangments.

For clinical advice on appropriate investigations, please contact our Molecular Pathology team.